Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

LYRA holding history

Lyra Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

LYRA overviewAll 13F holders of LYRAFull Q2 2026 holdings

Shares (Q1 2026)
0
Sold out in Q1 2026
Value
$0
% of portfolio
0.0%
Quarters held
20
Since Q1 2021
Holdings of LYRA by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q1 20260$00.0%−675−100.0%Sold outHolders
Q4 2025675$2.08K<0.1%−3,326−83.1%ReducedHolders
Q3 20254,001$26.1K<0.1%+3,999+199,950.0%AddedHolders
Q2 20252$18<0.1%−8,683−100.0%ReducedConverted for a 1-for-50 splitHolders
Q1 2025434,226$54.7K<0.1%+9,261+2.2%AddedHolders
Q4 2024424,965$87.5K<0.1%+400,050+1,605.7%AddedHolders
Q3 202424,915$6.40K<0.1%+10,218+69.5%AddedHolders
Q2 202414,697$4.07K<0.1%+14,679+81,550.0%AddedHolders
Q1 202418$112<0.1%−4,782−99.6%ReducedHolders
Q4 20234,800$25.2K<0.1%+4,782+26,566.7%AddedHolders
Q3 202318$70<0.1%00.0%UnchangedHolders
Q2 202318$74<0.1%−835−97.9%ReducedHolders
Q1 2023853$1.71K<0.1%−2,544−74.9%ReducedHolders
Q4 20223,397$10.7K<0.1%+303+9.8%AddedHolders
Q3 20223,094$15.0K<0.1%+1,072+53.0%AddedHolders
Q2 20222,022$11.0K<0.1%+2,004+11,133.3%AddedHolders
Q1 202218$00.0%−4,052−99.6%ReducedHolders
Q4 20214,070$18.0K<0.1%+4,052+22,511.1%AddedHolders
Q3 202118$00.0%−549−96.8%ReducedHolders
Q2 2021567$5.00K<0.1%−2,187−79.4%ReducedHolders
Q1 20212,754$32.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.